These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1668212)

  • 1. Central effects of Ro 19-6327 given acutely and repeatedly.
    Skuza G; Rogóz Z
    Pol J Pharmacol Pharm; 1991; 43(6):437-47. PubMed ID: 1668212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Some central effects of opipramol given repeatedly.
    Skuza G; Rogóz Z; Sowińska H
    Pol J Pharmacol Pharm; 1990; 42(5):425-31. PubMed ID: 2098752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antidepressant profile of 9-methyl-2[-3-(4-phenyl-1-piperazinylpropyl)]-1,2,3,4-tetrahydro-beta- carbolin-1-one (B-193).
    Wiczyńska B; Antkiewicz-Michaluk L; Pilc A; Chojnacka-Wójcik E; Przegaliński E
    Pol J Pharmacol Pharm; 1989; 41(4):331-44. PubMed ID: 2636891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some central effects of brofaromine given repeatedly are phase-dependent.
    Górka Z; Zajaczkowski W
    Pol J Pharmacol Pharm; 1990; 42(4):313-20. PubMed ID: 2097592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of venlafaxine, a new antidepressant, given acutely.
    Rogóz Z; Dziedzicka-Wasylewska M; Maj J
    Pol J Pharmacol; 1998; 50(2):107-15. PubMed ID: 9798262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant activities of WEB 1881, a new nootropic agent.
    Maj J; Rogóz Z; Skuza G; Sowińska H; Nowak G
    Pol J Pharmacol Pharm; 1989; 41(5):439-52. PubMed ID: 2561889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some central effects of tiflucarbine, a new potential antidepressant drug.
    Maj J; Rogóz Z; Sowińska H; Zalewski Z
    Pol J Pharmacol Pharm; 1987; 39(1):63-74. PubMed ID: 2823240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central effects of SL 82.0715, an antagonist of polyamine site of the NMDA receptor complex.
    Dereń-Wesołek A; Maj J
    Pol J Pharmacol; 1993; 45(5-6):467-80. PubMed ID: 7912135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central action of ketotifen.
    Rogóz Z; Skuza G; Sowińska H
    Pol J Pharmacol Pharm; 1981; 33(5):503-15. PubMed ID: 7335554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychopharmacological profile of mesterolone.
    Baran L; Przegaliński E
    Pol J Pharmacol Pharm; 1981 Oct; 33(3):299-303. PubMed ID: 7198778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central effects following repeated treatment with antidepressant drugs.
    Maj J
    Pol J Pharmacol Pharm; 1984; 36(2-3):87-99. PubMed ID: 6089162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of repeated administration of imipramine, citalopram and mianserin on responsiveness of central serotonergic, alpha 2-adrenergic and cholinergic system in mice.
    Maj J; Rogóz Z; Skuza G; Sowińska H
    Pol J Pharmacol Pharm; 1989; 41(4):313-9. PubMed ID: 2561380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central action of the antidepressant drug pirlindole.
    Maj J; Michaluk J; Rawłów A; Rogóz Z; Skuza G
    Arzneimittelforschung; 1986 Aug; 36(8):1198-201. PubMed ID: 3490854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of MAO-A and MAO-B selective inhibitors Ro 41-1049 and Ro 19-6327 on the deamination of newly formed dopamine in the rat kidney.
    Fernandes MH; Soares-da-Silva P
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1309-13. PubMed ID: 2124622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The central action of carbamazepine as a potential antidepressant drug.
    Maj J; Chojnacka-Wójcik E; Lewandowska A; Tatarczyńska E; Wiczyńska B
    Pol J Pharmacol Pharm; 1985; 37(1):47-56. PubMed ID: 4041037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of reboxetine, a representative of new class of antidepressant drugs, selective noradrenaline reuptake inhibitor (NARI), given acutely.
    Rogóz Z; Wróbel A; Krasicka-Domka M; Maj J
    Pol J Pharmacol; 1999; 51(5):399-404. PubMed ID: 10817540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
    Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
    Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some central effects of kynurenic acid, 7-chlorokynurenic acid and 5,7- dichloro-kynurenic acid, glycine site antagonists.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Pol J Pharmacol; 1994; 46(3):115-24. PubMed ID: 8000442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.